Task Force I: Direct Cardiovascular Implications of Emerging Infectious Diseases and Biological Terrorism Threats  by Baddour, Larry M. et al.
DE
r
i
e
r
r
b
u
o
i
i
t
f
i
t
s
t
i
l
i
n
N
o
s
i
s
H
t
1
t
a
i
(
b
c
p
w
Journal of the American College of Cardiology Vol. 49, No. 12, 2007
© 2007 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/07/$32.00
PTask Forces
Task Force I: Direct Cardiovascular
Implications of Emerging Infectious
Diseases and Biological Terrorism Threats
Larry M. Baddour, MD, Zhi-Jie Zheng, MD, PHD, Co-Chairs
Darwin R. Labarthe, MD, MPH, PHD, FAHA, Siobhán O’Connor, MD, MPH
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.019H
d
t
a
w
m
h
p
a
i
d
i
h
a
D
d
t
c
i
e
a
p
p
a
m
a
a
e
t
a
m
o
s
o
s
c
cefinition and Classifications
merging infections are those with a rising incidence over
ecent decades and those that threaten to increase, encompass-
ng both newly emerging and re-emerging infections. The
mergence of a new infectious agent in the population, the new
ecognition of a previously undetected circulating agent, or the
ealization that a noncommunicable disease is actually caused
y infection contribute to this group of microbial threats,
nrelated to any possible intentional release of biologic agents
r bioterrorism (1). As with the scope of the larger body of all
nfections and infectious diseases, the capacity of emerging
nfections to affect the cardiovascular system varies from none
o limited or increased risk. However, this task force report will
ocus on the possible cardiovascular implications of emerging
nfectious diseases and infection with select agents designated
o have potential for intentional release.
A wide range of infectious agents that can emerge in
pontaneous epidemics or be disseminated in bioterrorist at-
acks can affect the cardiovascular system. Many of these
nfectious agents have caused disease sporadically (e.g., botu-
ism, tularemia) or endemically (e.g., viral hemorrhagic fevers)
n certain parts of the world for centuries; others are relative
ewcomers (e.g., severe acute respiratory syndrome or SARS,
ipah virus). Some of these agents (e.g., smallpox) do not
ccur naturally at present and even one confirmed case would
ignal a likely bioterrorist event.
When focusing on the select potential agents of bioterror-
sm, as well as emerging infectious diseases, the clinical
yndromes catalogued by the U.S. Department of Health and
uman Services are as varied as the pathogens that produce
hem (2,3). With some, the direct clinical impact is limited to
organ system, as in the case of Clostridium botulinum
oxin-induced neuroparalytic illness (4). Other agents can
ffect multiple organ systems, as in the case of Coxiella burnetii
nfection, which affects both pulmonary and hepatic systems
5). Additional factors accentuate the complexity of
ioterrorism-related illnesses. The temporal onset of different
linical manifestations following exposure can vary. For exam-
le, Q fever endocarditis is an illness of chronic infection;
hereas pneumonia is seen acutely following exposure (5). kowever, naturally occurring infections with most of the
esignated bioterrorism agents are rarely seen in the U.S.
oday. Because of this, many clinicians are unfamiliar with the
ssociated clinical syndromes and may not initially recognize
hen an illness stems from exposure to one of these agents,
uch less from intentional release in a bioterrorism attack (6).
The Centers for Disease Control and Prevention (CDC)
as classified certain diseases and agents into 3 relatively high-
riority categories (A, B, and C) (2,3). These diseases and
gents are summarized in Tables 1 and 2. Diseases and agents
n Category A have the highest priority because they can be
isseminated or transmitted easily from person to person, result
n high mortality rates, have the potential for major public
ealth impact, may cause public panic and social disruption,
nd require special action for public health preparedness.
iseases and agents in Category B are moderately easy to
isseminate, result in moderate morbidity rates and low mor-
ality rates, and require specific enhancements of the diagnostic
apacity and enhanced disease surveillance. Diseases and agents
n Category C include emerging pathogens that could be
ngineered for mass dissemination in the future because of
vailability, ease of production and dissemination, and the
otential for high morbidity and mortality rates and major
ublic health impact.
This report focuses on the Category A, B, and C agents, but
n unlimited number of other potential, nonbioterrorism,
icrobial threats exist from natural evolution, transformation,
nd transmission of existing pathogens, including emerging
nd re-emerging infectious diseases, as well as from genetically
ngineered variants or “mosaics” that can multiply the potential
ransmissibility, morbidity, and mortality of agents released in
terrorist attack.
Many of the Category A, B, and C agents injure the
yocardium, pericardium, or endothelium by direct infection
r infiltration or through a chemical toxin (e.g., ricin). For
ome, the evidence of direct effects stems from multiple
bservations. For others, information rests on a single or a
mall set of anecdotal reports. Although such direct injury
ould harm even healthy individuals with a previously normal
ardiovascular system, the reality is that most of the currently
nown, high-risk agents are not directed at the cardiovascular
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he heart and vasculature when these agents cause prolonged or
evere fever, sepsis, shock, dehydration, central and peripheral
ervous system dysfunction, anemia, hypoxia, renal, and/or
epatic impairment.
Cardiovascular specialists should have a general working
nowledge of the common bioterrorist agents (6). Table 2
ighlights the clinical presentation, evaluation, and laboratory
esting for a number of diseases and agents that are of particular
oncern to our national security (3,7). It is important for
linicians to remember that although most of the Category A,
, and C agents are disseminated and transmitted by aerosol-
zed droplets or secretions that enter the victim via the
espiratory route (e.g., weaponized anthrax spores, ricin), no-
able exceptions exist (e.g., cutaneous anthrax exposure).
nown Cardiovascular Syndromes
ssociated With Category A, B,
nd C Agents and Diseases
our cardiovascular syndromes are caused by bioterrorism
ategories of Bioterrorism Agents and Diseases and Associated Ca
Table 1 Categories of Bioterrorism Agents and Diseases and A
Category Agents and Diseases
A Anthrax (Bacillus anthracis)
Highest priority—these agents can be
disseminated or transmitted easily
from person to person, result in
high mortality rates, might cause
public panic and social disruption,
and require special action for
public health preparedness.
Botulism (Clostridium botulinum toxin)
Plague (Yersinia pestis)
Smallpox (Variola major)
Tularemia (Francisella tularensis)
Viral hemorrhagic fevers, including filov
Ebola, Marburg), and arenaviruses (e
Machupo)
B Brucellosis (Brucella species)
Moderate priority—moderately easy
to disseminate, result in moderate
morbidity rates and low mortality
rates, and require specific
enhancements of CDC’s diagnostic
capacity and enhanced disease
surveillance.
Epsilon toxin of Clostridium perfringens
Food safety threats (e.g., Salmonella sp
Escherichia coli O157:H7, Shigella)
Glanders (Burkholderia mallei)
Melioidosis (Burkholderia pseudomall
Psittacosis (Chlamydia psittaci)
Q fever (Coxiella burnetii)
Ricin toxin from Ricinus communis (cas
Staphylococcal enterotoxin B
Typhus fever (Rickettsia prowazekii)
Alphaviruses (e.g., Venezuelan equine e
eastern equine encephalitis, western
encephalitis)
Water safety threats (e.g., Vibrio choler
Cryptosporidium parvum)
C
Low priority—could be engineered for
mass dissemination because of
availability, ease of production, and
the potential for high morbidity/
mortality rates.
Emerging infectious disease agents (su
virus, hantavirus)
he number of “” indicates the strength of the evidence on the association. *Includes large, megents: 1) endocarditis, 2) myocarditis, 3) pericarditis, and W) vasculitis. The heart is the primary site of endocarditis,
yocarditis, and pericarditis pathology, while vasculitis
ffects the vascular tissues. The mechanisms of pathology
re varied, ranging from direct tissue invasion by the
icrobe—transient or persistent—to complications of a
ocal or systemic immune response to infection.
Distinguishing the microbial etiology of each syndrome can
e challenging; whether intentionally released for bioterrorism
r naturally occurring, different infectious agents can cause
ndistinguishably similar clinical signs and symptoms. Thus, it
ay not be obvious to clinicians, at least early in a bioterrorism
ttack, that a cardiovascular syndrome is due to biological
arfare, especially if the biological agent does not grow or
rows slowly in the culture media routinely used by clinical
aboratories to detect naturally occurring pathogens. Charac-
eristic signs and symptoms of each of the 4 cardiovascular
yndromes are briefly outlined in the subsequent sections.
ndocarditis
he clinical features of infective endocarditis depend, in
art, on the virulence of the infecting organism(s), the
xposure dose, and the host response to that infection (8).
ascular Syndromes
iated Cardiovascular Syndromes
Endocarditis Myocarditis Pericarditis Vasculitis*
  
(e.g.,
ssa,
   
,    
 
  
  
ans)
alitis,
e
ipah hantavirus 
nd small vessel vasculitis plus cutaneous leukocytoclasric vasculitis.rdiov
ssoc
iruses
.g., La
ecies
ei)
tor be
nceph
equin
ae,
ch as Nith more aggressive pathogens, clinical evidence may
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Table 2 Summary of Select Category A and B Diseases and Agents (3,7)
Disease or Agent Infection Routes, Signs, and Symptoms Diagnostic Procedures
Category A Diseases and Agents
Anthrax (Bacillus anthracis) Cutaneous anthrax: About 95% of anthrax infections occur
through a cut or abrasion on the skin. The skin
infection begins as a raised itchy bump but within 1–2
days develops into a vesicle and then a painless ulcer,
usually 1–3 cm in diameter, with a characteristic black
necrotic (dying) area in the center. About 20% of
untreated cases of cutaneous anthrax result in death.
Inhalational anthrax: Initial symptoms may resemble
those of the common cold—sore throat, mild fever,
muscle aches, and malaise. After several days, the
symptoms may progress to severe breathing problems
and shock. Inhalation anthrax is usually fatal.
Gastrointestinal anthrax: Gastrointestinal anthrax is
characterized by acute inflammation of the intestinal
tract. Initial signs of nausea, loss of appetite, vomiting,
and fever are followed by abdominal pain, vomiting of
blood, and severe diarrhea. Intestinal anthrax results in
death in 25%–60% of affected individuals.
Anthrax is diagnosed by isolating B. anthracis from the blood, skin
lesions, or respiratory secretions or by measuring certain
antibodies in the blood.
Health care providers should confirm the diagnosis by obtaining
the appropriate laboratory specimens based on the clinical
form of the suspected anthrax: specimens of vesicular fluid and
blood for cutaneous anthrax, blood and cerebrospinal fluid (if
meningeal signs are present) or chest X-ray for inhalational
anthrax, and blood for gastrointestinal anthrax.
Botulism (Clostridium botulinum toxin) The classic symptoms of botulism include double vision,
blurred vision, drooping eyelids, slurred speech,
difficulty swallowing, dry mouth, and muscle weakness.
Infants with botulism appear lethargic, feed poorly, are
constipated, and have a weak cry and poor muscle
tone.
These are all symptoms of the muscle paralysis caused by
the bacterial toxin. If untreated, these symptoms may
progress to cause paralysis of the arms, legs, trunk,
and respiratory muscles. In foodborne botulism,
symptoms generally begin 18–36 h after eating a
contaminated food, but they can occur as early as 6 h
or as late as 10 days later.
Patient history and physical examination may suggest botulism
but are usually not enough to allow a diagnosis. Other
diseases, such as Guillain-Barré syndrome, stroke, and
myasthenia gravis, can produce symptoms that are similar to
those of botulism, and certain tests may be needed to exclude
these other conditions, including brain scan, spinal fluid
examination, nerve conduction test (electromyography), and
tensilon test for myasthenia gravis.
The most direct way to confirm the diagnosis is to identify the
botulinum toxin in the patient’s serum or stool by injecting the
samples into mice and looking for signs of botulism. The
bacteria can also be isolated from the stool of persons with
foodborne and infant botulism. These tests can be performed
at some state health department laboratories and the CDC.
Plague (Yersinia pestis) The typical sign of the most common form of human
plague is a swollen and very tender lymph gland,
accompanied by pain. The swollen gland is called a
“bubo” (hence, the term “bubonic plague”). Bubonic
plague should be suspected when a person develops a
swollen gland, fever, chills, headache, and extreme
exhaustion and has a history of possible exposure to
infected rodents, rabbits, or fleas.
The diagnosis of plague is confirmed if 1 of the following
conditions is met: 1) an isolated culture is lysed by a specific
bacteriophage; 2) 2 serum specimens demonstrate a 4-fold
anti-F1 antigen titer difference by hemagglutination testing; or
3) a single serum specimen tested by hemagglutination has an
anti-F1 antigen titer of 1:128 and the patient has no known
previous plague exposure or vaccination history.
Smallpox (Variola major) Acute onset of fever of at least 101°F (38.3°C) followed
by a rash characterized by firm, deep-seated vesicles or
pustules in the same stage of development without
other apparent cause.
Laboratory criteria for confirmation include: 1) PCR identification
of variola DNA in a clinical specimen, or 2) isolation of
smallpox (variola) virus from a clinical specimen (World Health
Organization Smallpox Reference Laboratory or laboratory with
appropriate reference capabilities) with variola PCR
confirmation.
The importance of case confirmation using laboratory diagnostic
tests depends on the epidemiological situation.
Tularemia (Francisella tularensis) Symptoms of tularemia include sudden fever, chills,
headaches, diarrhea, muscle aches, joint pain, dry
cough, and progressive weakness.
People with tularemia may also develop pneumonia with
chest pain and bloody sputum. They may experience
difficulty breathing or even stop breathing.
Other symptoms depend on the route of exposure to the
tularemia bacteria. These symptoms include ulcers on
the skin or mouth, swollen and painful lymph glands,
swollen and painful eyes, and sore throat.
Laboratory diagnosis of tularemia is based on culture or serology.
F. tularensis is a slow-growing, fastidious organism that
requires media containing cystine or cysteine for optimal
growth. Laboratory personnel should be alerted if tularemia is
suspected to ensure that proper media are used and to prevent
infection of laboratory workers. Serologic testing is available
through reference laboratories. Confirmation requires a 4-fold
change in anti-F. tularensis antibodies between paired sera.
Viral hemorrhagic fevers (filoviruses
[e.g., Ebola, Marburg] and
arenaviruses [e.g., Lassa, Machupo])
Signs and symptoms vary by the type of VHF, but initial
signs and symptoms often include marked fever,
fatigue, dizziness, muscle aches, loss of strength, and
exhaustion. Patients with severe cases of VHF often
show signs of bleeding under the skin, in internal
organs, or from body orifices such as the mouth, eyes,
or ears.
The Special Pathogens Branch of the CDC works with Biosafety
Level 4 viruses, which are highly pathogenic and require
handling in special laboratory facilities.Continued on next page
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Table 2 Continued
Disease or Agent Infection Routes, Signs, and Symptoms Diagnostic Procedures
Ricin toxin from Ricinus communis
(castor beans)
Inhalation: Within a few hours of inhaling ricin, typical
symptoms are respiratory distress, fever, cough,
nausea, and chest tightness. Heavy sweating may
follow and fluid may accumulate in the lungs
(pulmonary edema). Finally, low blood pressure and
respiratory failure may occur, leading to death.
Ingestion: Symptoms after swallowing ricin include
vomiting, diarrhea that may become bloody, and severe
dehydration followed by low blood pressure.
Skin and eye exposure: Ricin in powder or mist form can
cause redness and pain in the skin and eyes.
Death from ricin poisoning may occur within 36 to 72 h of
exposure, depending on the route of exposure and the
dose received. If death has not occurred within 3 to 5
days, the victim is likely to recover.
When an environmental sample is believed to contain ricin, the
sample should be sent directly to a Laboratory Resource
Network reference laboratory for testing using a time-resolved
fluorescence immunoassay. If the sample tests positive for
ricin, it may be sent to the CDC for additional PCR testing,
defining, archiving, or storing.
Category B Diseases and Agents
Brucellosis (Brucella spp.) The most common route of infection is eating or drinking
contaminated milk products. Brucellosis is rarely due to
inhalation of Brucella organisms, but this may be a
significant hazard for people in certain occupations.
Persons working in slaughterhouses or meat-packing
plants and veterinarians are at increased risk of
contamination of skin wounds.
Brucellosis can cause a range of symptoms that are
similar to those of the flu, including fever, sweats,
headaches, back pain, and physical weakness. Severe
infections of the central nervous system or heart lining
may occur. Brucellosis can also cause long-lasting or
chronic symptoms, such as recurrent fevers, joint pain,
and fatigue.
Brucellosis is diagnosed in a laboratory by identifying Brucella
organisms in samples of blood or bone marrow. In addition,
blood tests can detect antibodies against the bacteria. To
confirm a diagnosis using a blood test, the provider should
collect an initial blood sample and a second blood sample 2
weeks later.
Q fever (Coxiella burnetii) Only one-half of all people infected with C. burnetii show
signs of clinical illness. Most acute cases of Q fever
begin with sudden onset of one or more of the
following: high fevers, severe headache, general
malaise, myalgia, confusion, sore throat, chills, sweats,
nonproductive cough, nausea, vomiting, diarrhea,
abdominal pain, and chest pain. Fever usually lasts 1
to 2 weeks. Weight loss can occur and persist for some
time. Up to one-half of all patients with a symptomatic
infection develop pneumonia. Most people with Q fever
have abnormal liver function test results, and some
develop hepatitis.
Confirming a diagnosis of Q fever requires serologic testing to
detect the presence of antibodies to C. burnetii antigens. In
most laboratories, the indirect immunofluorescence assay is
the most dependable and widely used method. C. burnetii may
also be identified in infected tissues using
immunohistochemical staining and DNA detection methods.
Psittacosis (Chlamydia psittaci) When a person breathes in Chlamydia psittaci, the lungs’
defense mechanisms attempt to neutralize the bacteria.
The bacteria that avoid this defense start an infection that
ranges in severity from a mild flu-like illness to severe
pneumonia. Generally, signs and symptoms appear within
4 to 15 days after exposure and include fever, chills,
cough, weakness or fatigue, muscle and chest pain, loss
of appetite, nausea, vomiting, diarrhea, headache,
sweating, and abnormal intolerance to light.
Psittacosis is primarily a lung disease, but it can involve
several organs. Some reports show that inflammation
can occur in the liver, heart cavity lining, heart muscle,
and brain.
Psittacosis can be diagnosed most often by 1) the isolation of
Chlamydia psittaci from respiratory secretions, 2) a 4-fold or
greater increase in antibody against C. psittaci by complement
fixation or MIF to a reciprocal titer of greater than or equal to
32 between paired acute- and convalescent-phase serum
specimens, or 3) the presence of immunoglobulin M antibody
against C. psittaci by MIF to a reciprocal titer of greater than or
equal to 16.
Salmonellosis (Salmonella spp.) Most persons infected with Salmonella develop diarrhea,
fever, and abdominal cramps within 12 to 72 h after
infection. The illness usually lasts 4 to 7 days, and
most persons recover without treatment. However, in
some persons the diarrhea may be so severe that the
patient needs to be hospitalized. In these patients, the
Salmonella infection may spread from the intestines to
the bloodstream and then to other body sites and can
cause death unless the person is treated promptly with
antibiotics. The elderly, infants, and those with
impaired immune systems are more likely to develop
severe illness.
To identify Salmonella as the cause of the illness, providers should
send stool samples to the laboratory for testing to identify the
presence of Salmonella. To ensure that the appropriate tests
are conducted, providers must instruct the laboratory to look
for Salmonella. Once Salmonella has been identified, further
testing can determine its type and which antibiotics should be
used to treat it.Continued on next page
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ith less virulent microorganisms, the onset of infection is
ore subtle and initially nonspecific, often delaying diag-
osis by weeks or even months.
A majority of patients manifest fever. Other signs of
ystemic toxicity or sepsis may be present with endocarditis
ue to aggressive pathogens but are usually absent in
atients with subacute to chronic infection. Other nonspe-
ific findings include chills, malaise, fatigue, night sweats,
eakness, weight loss, myalgias, and arthralgias.
The development of secondary complications of endocar-
itis often prompts a consideration of the correct diagnosis.
his includes the presence of a cardiac murmur due to
alvular insufficiency (or rarely, stenosis) caused by destruc-
ion of components of the valve apparatus. Other indica-
ions of infective endocarditis are signs of left- or right-
ided ventricular failure and systemic or pulmonary vascular
mbolic events, including acute evidence of tissue damage or
rgan dysfunction, such as stroke, pleuritic chest pain,
xtremity or digit ischemia, and visual loss.
Blood cultures are critical to establish the diagnosis and
he etiology of infective endocarditis cases and other syn-
romes of intracardiac or intravascular infection. When a
lood culture is negative due to recent administration of
ntibiotics or the fastidious growth characteristics of the
nfecting pathogen (such characteristics are manifested by
ome of the bioterrorism agents), the diagnosis of endocar-
itis may be less obvious, particularly if only nonspecific
linical findings are present. In such cases, echocardiogra-
hy, particularly transesophageal echocardiography in
dults, may be used to establish a diagnosis of endocarditis
8,9). Similarly, serology (detection of antibodies to the
nfectious agent), immunohistochemistry, and testing for
he presence of pathogen deoxyribonucleic acid, may be key
o the diagnosis of blood and tissue culture-negative endo-
ontinued
Table 2 Continued
Disease or Agent Infection Routes, Signs, and S
Melioidosis (Burkholderia
pseudomallei)
Transmission occurs by direct contact wi
soil and surface waters. In southeast
organism has been repeatedly isolate
fields, with infection occurring primari
season. Humans and animals are beli
the infection by inhalation of dust, ing
contaminated water, and contact with
soil, especially through skin abrasions
troops, by contamination of war woun
person transmission can occur.
Illness from melioidosis can be categoriz
localized infection, actue pulmonary in
bloodstream infection, and chronic su
infection. Inapparent infections are al
incubation period (time between expo
appearance of clinical symptoms) is n
but may range from 2 days to many y
etailed description on these agents and diseases is available on the Web site of the Centers fo
gentlist.asp (3).
CDC  Centers for Disease Control and Prevention; DNA  deoxyribonucleic acid; MIF  microarditis (10). These latter methods of diagnosis are partic- Llarly useful to identify certain naturally occurring patho-
ens that could be used for bioterrorism attacks, including
oxiella burnetii, Franciscella tularensis, and Chlamydia
sittaci.
yocarditis
yocarditis is associated with many more infectious and
oninfectious causes than endocarditis. In addition, seasonal
utbreaks of myocarditis may occur as a result of several viral
tiologies. As a result, clinicians are likely to link an
ncreased number of myocarditis cases to a viral epidemic,
hich could delay the recognition of a bioterrorism attack.
Unlike infective endocarditis, myocarditis can be asymp-
omatic and, depending on the etiology, may resolve itself
ithout specific antimicrobial treatment (11,12). Thus,
ost cases of myocarditis are undiagnosed. This makes it
ifficult to quantify a background rate in the population and
o detect any increased frequency of myocarditis induced by
hanging infectious exposures. When symptoms do occur,
hest pain is predominant and palpitations, shortness of
reath, and cough may be present. Additional signs of
yocarditis include recent or current fever, tachycardia,
ericardial friction rub, signs of congestive heart failure, and
he presence of a third heart sound.
Cardiomegaly and vascular congestion on chest radio-
raph and ST-segment elevation and T-wave inversion on
erial electrocardiograms may be present (11). Echocardio-
ram and cardiac magnetic resonance imaging (MRI) with
adolinium are useful for assessing ventricular wall motion
nd left ventricular ejection fraction (11). Inflammatory
hanges in the myocardium may be seen on MRI showing
reas of reduced contrast perfusion and enhanced delayed
entricular wall uptake.
These symptoms, signs, and diagnostic indicators, how-
ver, are common to myocarditis of multiple etiologies.
ms Diagnostic Procedures
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A definitive diagnosis can be made by growing B. pseudomallei
from any site, including blood cultures, pus aspirated from an
abscess, sputum, or urine cultures. A throat swab is not
sensitive but is 100% specific if positive. Ashdown’s medium,
containing gentamicin, may be required for cultures from
nonsterile sites. Burkholderia cepacia medium may be a useful
alternative selective medium in nonendemic areas. A new
medium derived from Ashdown known as Francis media can
help differentiate B. pseudomallei from B. cepacia and helps in
the early diagnosis of melioidosis. Diagnosis of melioidosis can
be made as early as 18 h using Francis media.
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esponse to a particular infection, are needed to delineate
he infectious etiology—whether naturally occurring or due
o an intentional bioterrorist release. The clinician must be
repared (perhaps educated or trained) to recognize the
rray of potential etiologies of myocarditis, including in this
ontext, the rarer potential select agent causes and the rare
ossibility of a bioterrorism event. Clinicians should also be
amiliar with the route to appropriate testing of adequately
ollected and processed specimens at a proficient laboratory
nd to alerting public health officials of unusual findings so
hey might assess for a cluster or larger group of cases and,
f found, investigate the cause.
ericarditis
any conditions affect both the myocardium and the
ericardium. Primary involvement of one or the other
ardiac structure, however, is usually clinically definable
13,14).
Chest pain is the most common symptom of pericarditis.
he pain is usually, but not always, associated with a rub
eard on cardiac auscultation and is typically worse when
he patient lies supine, swallows, or takes deep breaths. The
ndividual may experience fever, as well as dyspnea that
ould be a manifestation of cardiac tamponade due to
ericardial effusion caused by pericarditis. Other evidence of
amponade may include a pulsus paradoxus greater than 10
m Hg and a prominent X descent with loss of the Y
escent in the jugular venous pressure.
An electrocardiogram usually shows ST-segment eleva-
ion in all lead tracings as early changes in pericarditis.
arge pericardial effusions may cause reduced QRS voltage
nd electrical alternans. Echocardiography is an important
ool to determine whether an effusion is present and to
stimate its size and whether early hemodynamic compro-
ise exists due to the effusion in the pericardial space (14).
dentification of an infectious etiology is important since
nterventions are available for certain bacteria. Blood cul-
ures, serology, polymerase chain reaction (PCR), or reverse
ranscriptase-PCR of blood, its components, and even
ericardial fluid assist in this diagnosis.
asculitis
nfection of the peripheral vascular system has been re-
orted with several of the potential infectious select agents
f bioterrorism. In vasculitis, the involvement ranges from
nfection and inflammation with or without mycotic aneu-
ysm of large and medium vessel walls to that of small
essels and even superficial cutaneous leukocytoclastic vas-
ulitis; for each implicated infectious etiology, the available
ody of evidence varies from large to anecdotal. As with
ndocarditis and myocarditis, this complication of bacterial
r viral infection is more often attributed to common agents
han to the possible select agents of bioterrorism.
In some vasculitis cases, infection of the arterial wall may
ot be apparent. In some, local, systemic, or both clinical panifestations occur (15,16). Local findings include pain
ue to aneurysmal dilation of the arterial wall. In addition,
essel rupture with bleeding can cause pain. Pain may also
e due to arterial emboli that precipitate local or distal
schemia. The findings of distal ischemia include skin
hanges, diminishment or absence of palpable pulse, and
ventual gangrene. A mass may be palpable with aneurysm
r aneurysm formation. Bleeding, when in the brain or
entral nervous system, may present as severe headache,
eurologic deficit, and/or mental status decline. Local soft
issue findings of inflammation may be apparent when more
uperficial arteries, usually in an extremity, are infected.
astrointestinal bleeding, which can range from indolent to
evere and sudden, may complicate abdominal aortic aneu-
ysms that erode into the gastrointestinal tract.
The systemic findings of vasculitis include sepsis. In
hese patients, blood cultures are usually positive and
eukocytosis is frequently present. Relapsing bacteremia
ollowing an initial course and response to antibiotics
ay be a valuable clue to the correct diagnosis. Depend-
ng on the cause, serology and PCR can be valuable
djuncts to the diagnosis of vasculitis and identification
f an infectious etiology, as could culture, immunopa-
hology, and molecular diagnostic tools (e.g., PCR) of
ny surgical resection or biopsy tissue.
The choice of imaging modality to evaluate whether an
neurysm is present varies depending on location of the
nfection. For intracranial evaluation, cerebral arteriography
s optimal, although MRI angiography is also used. Com-
uted tomography scanning is useful for aortic examination
nd for more distal arteries. Echocardiography is useful for
valuation of the most proximal segment of the aorta.
elect Diseases and Agents That
ay Affect the Cardiovascular System
elect Category A and B bioterrorism agents or diseases and
he cardiovascular syndromes they may produce are summa-
ized in Table 1 and described in more detail in the
ollowing text. These descriptions are based on the review of
xisting reports in the literature through a systematic liter-
ture search on PubMed. For all except Q fever, cardiovas-
ular syndromes are uncommonly reported.
ategory A Diseases and Agents
ularemia
irect involvement of cardiovascular structures by Fran-
isella tularensis, the agent of tularemia, is clinically rare.
nly 1 case of infective endocarditis has been described
17), so that characterization of the illness is not possible.
ericarditis has been reported in a small number of patients,
oth in the pre-antibiotic era (18) and recently (19). In these
atients, concomitant pneumonia was frequent, and the
resentation was acute.
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rucellosis
nfection due to Brucella species is uncommon in the U.S.
ardiovascular complications have been reported to occur in
% or less of patients who develop brucellosis. Infective
ndocarditis is the most common cardiovascular syndrome
n these individuals. Most reported cases of Brucella-
ssociated endocarditis have occurred in males, age 40 years
nd younger (20,21). These individuals present with a
hronic infection, and valvular cusp calcification (22).
Endocarditis can complicate both pre-existing normal
nd abnormal cardiac valves. The aortic valve is most often
nvolved, but lack of use of transesophageal echocardiogra-
hy could underestimate the frequency of mitral valve
nfection, in addition to structural complications. Myocar-
ial abscess and systemic embolization may occur, although
ess frequently than with other types of bacterial endocar-
itis (23). The usual cause of death due to Brucella endo-
arditis is congestive heart failure (23).
Other rare cardiovascular syndromes associated with bru-
ellosis include myocarditis, pericarditis, and infective end-
rteritis. However, the numbers of cases with each syn-
rome is so small that characterization of these conditions is
ifficult (24–28). It is important to note, however, that
ortic involvement with mycotic aneurysm formation is
ften associated with infective spondylodiscitis due to Bru-
ella species (29,30).
sittacosis
ases of psittacosis-associated endocarditis, myocarditis,
nd pericarditis have been described (31–33). Mortality is
requent among patients with Chlamydia psittaci-associated
nfective endocarditis, who typically present with highly
estructive valvular infection (33). Some patients experience
ulmonary complaints, which is consistent with the route of
xposure to the pathogen. Respiratory symptoms have also
een identified in cases of myocarditis and pericarditis due
o C. psittaci. Because congestive heart failure can compli-
ate all 3 syndromes (endocarditis and myocarditis most
ommonly), it may be difficult to determine whether C.
sittaci is directly or indirectly responsible for the pulmonary
ymptoms.
A history of avian contact is commonly reported among
umans who develop cardiac infection due to C. psittaci.
ulture of the organism from blood and infected tissues is
ifficult. Because of the rarity of cardiac infection produced
y C. psittaci, clinicians rarely order serology or immuno-
istochemical studies for this agent, and the sensitivity and
pecificity of testing in clinical laboratories may vary. Thus,
nfection may remain undiagnosed.
Fever
fever is a worldwide zoonosis caused by Coxiella burnetii,
strictly intracellular, gram-negative bacterium, which livesn the monocyte/macrophage, its host phagocytic cell. It is sparticularly infectious organism, with the minimal infec-
ive dose being 1 to 5 organisms, and it is usually transmit-
ed following contact with infected animals (34,35).
Clinically, the disease is polymorphic and nonspecific and
ay present in an acute or chronic form. The most common
igns and symptoms of acute Q fever are prolonged fever or
u-like syndrome of unexplained origin, granulomatous
epatitis, and atypical pneumonia, although up to 50% of
atients may be asymptomatic (5,36,37).
Infective endocarditis is the major manifestation of
hronic Q fever (5,37), but routine blood cultures of affected
atients are often negative for C. burnetii (38). Q fever
ndocarditis is estimated to account for at least 5% of the
ore than 800 cases of endocarditis diagnosed in France
rom 1949 through 2000 (36).
The major risk factors for developing chronic endocardi-
is following Q fever are pre-existing valvular disease,
specially a prosthetic valve, and other comorbidities, such
s cancer (39). Currently, most cases of Q fever endocarditis
re diagnosed serologically by detecting antibodies to C.
urnetii (40). High levels of anti-phase I antibodies are
ound in individuals with chronic Q fever, while anti-phase
I antibodies predominate in acute Q fever. Diagnosis of Q
ever endocarditis can also be made by isolating C. burnetii
n cell culture, by PCR, or by immunohistochemistry (40).
Myocarditis has been reported as a manifestation of C.
urnetii infection, with approximately 30 cases of acute and
hronic Q fever cited in the literature over the last 20 years
41–43). Myocarditis occurred in 0.6% to 0.8% of patients
ith acute Q fever in 2 case series of 1276 and 1117 patients
41,42). Dyspnea, chest pain, and palpitation were the most
ommon symptoms. Many patients also experienced dilated
ardiomyopathy, which usually led to heart failure (41).
nly 1 case of pericarditis with C. burnetii infection has
een reported (44).
The long-term effects of Q fever on the cardiovascular
ystem are not clear. A study of a large outbreak of Q fever
n 1983 in Switzerland suggested that people with Q fever
ave an increased risk of vascular disease after 12 years of
ollow-up (45). However, another follow-up study of 147
atients from the 1989 Q fever outbreak in Birmingham,
nited Kingdom, did not find any increased risk (46).
Confirming a diagnosis of Q fever requires serologic
esting to detect the presence of antibodies to C. burnetii
ntigens. In most laboratories, the indirect immunofluores-
ence assay is the most dependable and widely used method.
. burnetii may also be identified in infected tissues using
mmunohistochemical staining and deoxyribonucleic acid
etection methods.
almonellosis
nfections due to salmonellae are common, and their inci-
ence appears to be increasing in the U.S. and other
ountries (47,48). Although S. Typhi and S. Paratyphi infect
umans only, the nontyphoidal salmonellae are widely
pread in nature and are commonly found in some animal
s
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hoidal salmonellae are important foodborne pathogens
hat cause gastroenteritis, bacteremia, and subsequent focal
nfection. In the U.S., an estimated 1.4 million Salmonella
nfections occur annually, resulting in approximately 45 000
ospitalizations and 600 deaths (48–50). Salmonellosis
ccounts for about 30% of deaths resulting from foodborne
llnesses in the U.S. (48).
The major risk factors for salmonellosis and bacteremia
re extremes of age and certain immunocompromised con-
itions, such as alteration of endogenous bowel flora of the
ntestine, diabetes, malignancy, autoimmune disorders, re-
iculoendothelial blockade, HIV infection, therapeutic im-
unodeficiency, and sickle cell anemia (51–53). Anatomical
isruptions, including atherosclerotic endovascular lesions
nd prosthetic devices, may serve as foci for persistent
almonella infection.
Salmonella infection may present in 5 different clinical
orms: 1) asymptomatic chronic carrier status, 2) gastroen-
eritis, 3) enteric fever, 4) bacteremia, and 5) extraintestinal
ocalized complications (54). The most serious (although
are) complication is the development of endovascular
nfection (e.g., endocarditis and infected aortic aneurysm).
he prognosis for patients with these conditions is poor.
almonella endocarditis usually occurs in patients with
re-existing heart problems and often causes severe valvular
estruction, with a case fatality rate of 70% (54). About
ne-fourth of Salmonella endocarditic cases are nonvalvular
mural); and one-fourth of Salmonella endocarditic patients
ave associated lumbar osteomyelitis; however, their survival
ates have not been reported (54). Salmonella pericarditis
ften presents with cardiac or pulmonary symptoms, but
ypical signs of pericardial disease (pulsus paradoxus, friction
ub) or characteristic electrocardiograph changes (low volt-
ge, elevated ST-segments) are uncommon. Salmonella may
lso infect the peripheral or visceral arteries, but the abdom-
nal aorta is the most frequent site of vascular infection (55).
ost of these patients are men over the age of 50 years with
re-existing atherosclerosis of the aorta who do not have a
revious history of gastroenteritis and no survival with
edical therapy alone has been reported. Salmonellae may
lso cause rare cases of myocarditis, but the pathogenesis is
nclear (56,57).
The diagnosis of an endovascular infection is often not
stablished until an advanced stage. But early diagnosis,
efore infection spreads to other areas of the circulatory
ystem, is crucial for survival. To identify Salmonellae as the
ause of the illness, providers should send stool samples to
he laboratory for testing when gastrointestinal symptoms
ccur. Once Salmonella has been identified, further testing
an determine its type and which antibiotics should be used
o treat it.
In addition to antibiotic therapy, surgical removal of
nfected areas may be required. Guidelines for surgical
emoval have been proposed and these, along with increasedse of ampicillin for endovascular infection, may be respon-
ible for the increased survival rates in recent years.
elioidosis
irect clinical involvement of cardiovascular structures by
urkholderia pseudomallei, the agent of melioidosis, is rare.
nly 2 cases of pericardial melioidosis have been described
58,59) so characterization of this illness is not possible.
asculitis (mycotic aneurysm) due to B. pseudomallei has
een described but is also a rare event.
In 1 literature review that described 12 cases of mycotic
neurysm due to B. pseudomallei, only 2 of the patients had
ortic arch involvement (60). The ages of these 12 patients
anged from 42 to 70 years, suggesting a possible predilec-
ion to atherosclerosis. Among 9 cases with a reported
nderlying illness, 1 had diabetes mellitus, 1 had hyperten-
ion, and 1 had prior B. pseudomallei infection. Trauma and
oil exposure were noted in only 3 patients, and 3 patients
ied due to infectious complications. The areas of case
rigin include southeast Asia, Taiwan, Mainland China,
nd Australia, consistent with the indigenous distribution of
he bacterium. A single case of cutaneous polyarteritis
odasa associated with B. pseudomallei has been also de-
cribed in a young Thai woman (61).
ummary Statement
ecent events have demonstrated that bioterrorists have the
bility to disseminate biologic agents in the U.S. and may be
apable of causing widespread social panic. Health care
roviders including cardiologists can play a key role in the
nitial recognition of a potential bioterrorism attack (62,63).
y being familiar with infectious agents of highest priority,
roviders can expedite diagnosis and initial management,
nd lead to a successful public health response to such
ttacks. Many resources are available to health care provid-
rs to learn more about relevant agents and diseases, as well
s their effects on cardiovascular system.
The Task Force thus recommends that health care
roviders:
. Be familiar with major agents and diseases that may
be used for bioterrorism attacks, as categorized and
described by the CDC (3,7). Detailed information on
these agents and diseases can be obtained through
CDC’s Web site at http://www.bt.cdc.gov/agent/
agentlist.asp. A summary description of the select
Category A and B diseases and agents is presented in
Table 2.
. Be aware of signs and symptoms and the clinical
diagnosis and management of the 4 major cardiovascular
syndromes—endocarditis, myocarditis, pericarditis, and
vasculitis—that certain potential bioterrorism agents
might induce.
34
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Category A agents is found to produce disease in a
single patient in the absence of obvious risk factors. The
likelihood of bioterrorism involvement increases signif-
icantly if more than 1 patient presents with illness from
1 of these agents.
. Ensure that clinical laboratories save isolates from cases
that may represent illness from biologic agents of
bioterrorism and contact state health departments for
guidance.
. Obtain thorough family and environmental histories
from patients to ascertain whether other close contacts
have had similar illnesses.
. Clinicians should be familiar with the public health
reporting requirements in their locale. Contact infection
control personnel and appropriate public health author-
ities if a patient is diagnosed with any of these agents or
diseases.
onclusions
e have shown that multiple infectious agents with the
otential for use in a bioterrorist attack could have a
rofound impact on the cardiovascular system of the af-
ected individuals, especially in those with underlying car-
iovascular disease. Cardiologists and other health care
roviders need to familiarize themselves with these agents
nd diseases, as well as with symptoms they are likely to
ause. In this way, they can be prepared to quickly identify
he potential involvement of a bioterrorist agent or disease
n a patient’s condition to both provide appropriate treat-
ent and assist the appropriate authorities in responding
uickly to a potential attack.
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Task Force II: Indirect and Secondary Cardiovascular
Effects of Biological Terrorism Agents and Diseases
Joseph P. Ornato, MD, FACC, FACP, FACEP, FAHA, James E. Muller, MD, FACC, FAHA, Co-Chairs
Erika S. Froelicher, RN, MA, MPH, PHD, FAHA, Robert A. Kloner, MD, PHD, FACC, FAHAackground
ioterrorist events can produce a variety of secondary
ardiovascular effects. For example, mass vaccination cam-
aigns to combat such potential bioterrorist agents as
mallpox can lead to cardiovascular symptoms in some of
hose who receive the vaccine. The acute and posttraumatic
sychological stress experienced by those affected (directly
r indirectly) by the bioterrorist event may trigger acute
ardiovascular events (such as heart attacks, sudden deaths,
trokes) or exacerbate existing cardiovascular symptoms. In
ddition, a large-scale terrorist event could overwhelm theommunity’s ability to provide timely care for patients with
he more conventional but time-dependent medical and
urgical cardiovascular emergencies.
In this report, we describe the secondary or indirect cardio-
ascular effects of the agents and diseases that are most likely to
e used for bioterrorism. These include the impact of the stress
roduced by bioterrorism on cardiovascular health and the
ardiovascular complications of smallpox vaccine. We then
escribe the pathophysiological processes through which bio-
errorist attacks could trigger cardiovascular events, followed by
uggestions for how to prevent or treat cardiovascular events
uring terrorist attacks and the implications for health care
olicy and future research.
